Literatur zu

**Muskelrelaxanzien**

Sugammadex: Eine neue Ära in der Antagonisierung von Muskelrelaxanzien

Christopher Rex • Friedrich K. Pühringer

1 Adam JM, Bennett DJ, Bom A et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem 2002; 45: 1806–1816


8 de Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: A multicenter, dose-finding and safety study. Anesthesiology 2007; 107(2): 239–245


14 Kam dePJ, Kuijk van J, Smeets J, Thomsen T, Peeters P. Single iv use sugammadex up to 32 mg/kg are not associated with QT/QTc prolongation. Anesthesiology 2007; 105: A1580


17 Peeters PAM, Passier PCCM, Smeets JWM, van Iersel T, Zwiers A. Single intravenous high-dose sugammadex (up to 96 mg/kg) is generally safe and well tolerated in healthy volunteers. Eur J Anaesthesiol 2008; 25(Suppl. 44): 9AP2–6


22 Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Østergaard D, Prins ME, Vibly-Mogensen J. Reversal of rocuronium-induced neuromuscular block by the selective
relaxant binding agent sugammadex: A dose-finding and safety study. Anesthesiology 2006; 104: 667–674


